In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.

Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have received renewal of a major federal grant to continue their collaboration to test and develop new treatments and vaccines against HIV/AIDS — and now COVID-19.

Health care workers, who have been disproportionately affected by the COVID-19 pandemic, will be the first tier of Vanderbilt University Medical Center employees to receive vaccine to prevent SARS-CoV-2 infection.

Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.

Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.

COVID-19 spreads faster and more widely throughout U.S. households than previously reported, according to new preliminary research from a multicenter study led by Vanderbilt University Medical Center researchers and published in, a weekly report from the Centers for Disease Control and Prevention (CDC).